A US district court has upheld patents on Amgen‘s Sensipar drug, used in the treatment of chronic kidney disease.
Pharmaceutical major Teva Pharmaceutical had attempted to market a generic version of the drug, but Amgen’s most recent patent on Sensipar does not expire until 2018.
Sensipar is used to treat secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis, and high levels of calcium in patients suffering from parathyroid carcinoma.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData